Filter Results
Clinical Studies
Results filtered:Study status:
Open
Closed for Enrollment
Open
-
A Phase I, Open-Label, Single/Multiple Dose, Dose-escalation Study To Evaluate The Safety, Tolerability And Antitumor Activity Of TX103 CAR-T Cell Injection (TX103) In Subjects With Recurrent Or Progressive Grade 4 Glioma.
Scottsdale/Phoenix, AZ
Jacksonville, FL
Rochester, MN
This is a phase I, open-Label, single/multiple dose, dose-escalation study to evaluate the safety, tolerability and antitumor activity of anti-B7-H3 CAR-T cell injection (TX103) in subjects with recurrent or progressive Grade 4 Glioma.The study also plan to explore the Maximum Tolerated Dose (MTD) and determine the Recommended Phase II Dose (RP2D) of the CAR-T cell therapy.
Closed for Enrollment
-
A Phase II Study Of Checkpoint Blockade Immunotherapy In Patients With Somatically Hypermutated Recurrent Glioblastoma
Scottsdale/Phoenix, AZ
Eau Claire, WI
Jacksonville, FL
La Crosse, WI
Rochester, MN
The purpose of this study is to evaluate the effect of immunotherapy drugs (ipilimumab and nivolumab) in treating patients with glioblastoma that has come back (recurrent) and carries a high number of mutations. Cancer is caused by changes (mutations) to genes that control the way cells function. Tumors with high number of mutations may respond well to immunotherapy. Immunotherapy with monoclonal antibodies such as ipilimumab and nivolumab may help the body's immune system attack the cancer and may interfere with the ability of tumor cells to grow and spread. Giving ipilimumab and nivolumab may lower the chance of recurrent glioblastoma with high number of mutations from growing or spreading compared to usual care (surgery or chemotherapy).
-
Brain Tumor Repository
Scottsdale/Phoenix, AZ
The main objective of the Brain Tumor Repository is to allow access to coded patient data by researchers both inside and outside of the Mayo Clinic system so that important research questions can be answered.
.